Vertex Pharmaceuticals (VRTX) Total Current Liabilities (2009 - 2026)

Vertex Pharmaceuticals has reported Total Current Liabilities for 18 years, with the latest figure at $3.9 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 2.57% year-over-year to $3.9 billion; the trailing twelve-month figure through Mar 2026 stood at $3.9 billion (up 2.57% YoY), and the FY2025 full-year result was $3.9 billion, up 8.32% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $3.9 billion, up from $3.9 billion in the prior quarter.
• The five-year high for Total Current Liabilities was $4.5 billion in Q3 2025, with the low at $2.2 billion in Q1 2022.
• Average Total Current Liabilities over 5 years is $3.4 billion, with a median of $3.6 billion recorded in 2024.
• Year-over-year, Total Current Liabilities surged 39.19% in 2022 and fell 0.33% in 2025.
• Tracing VRTX's Total Current Liabilities over 5 years: stood at $2.7 billion in 2022, then rose by 29.37% to $3.5 billion in 2023, then rose by 0.48% to $3.6 billion in 2024, then increased by 8.32% to $3.9 billion in 2025, then climbed by 0.5% to $3.9 billion in 2026.
• The last three Total Current Liabilities figures came in at $3.9 billion (Q1 2026), $3.9 billion (Q4 2025), and $4.5 billion (Q3 2025), per Business Quant data.

Peer Comparison